List of Zioptan drug patents

Zioptan is owned by Akorn.

Zioptan contains Tafluprost.

Zioptan has a total of 3 drug patents out of which 1 drug patent has expired.

Expired drug patents of Zioptan are:

  • US5886035

Zioptan was authorised for market use on 10 February, 2012.

Zioptan is available in solution/drops;ophthalmic dosage forms.

Zioptan can be used as reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

The generics of Zioptan are possible to be released after 28 May, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5886035 AKORN Difluoroprostaglandin derivatives and their use
Dec, 2022

(a month ago)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10864159 AKORN Method and composition for treating ocular hypertension and glaucoma
May, 2029

(6 years from now)

US9999593 AKORN Method and composition for treating ocular hypertension and glaucoma
May, 2029

(6 years from now)

Drugs and Companies using TAFLUPROST ingredient

Market Authorisation Date: 10 February, 2012

Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ZIOPTAN before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in